Skip to main content
Veterinary Medicines

HIPRAGUMBORO CW

Authorised
  • Infectious bursal disease virus, strain CH/80, Live

Product identification

Medicine name:
HIPRAGUMBORO CW
HIPRA GUMBORO CW, lüofilisaat joogivees manustamiseks
Active substance:
  • Infectious bursal disease virus, strain CH/80, Live
Target species:
  • Chicken (broiler)
Route of administration:
  • In drinking water use

Product details

Active substance and strength:
  • Infectious bursal disease virus, strain CH/80, Live
    31622800.00
    cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for use in drinking water
Withdrawal period by route of administration:
  • In drinking water use
    • Chicken (broiler)
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD09
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • box containing 1 vial of 10000 doses
  • box containing 1 vial of 5000 doses
  • box containing 1 vial of 1000 doses
  • box containing 10 vials of 10000 doses
  • box containing 10 vials of 1000 doses
  • box containing 10 vials of 5000 doses

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 2109
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0162/001
Concerned member states:
  • Austria
  • Belgium
  • Denmark
  • Estonia
  • France
  • Germany
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Slovakia
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 23/01/2024

eu-PUAR-hipragumboro-cw-en.pdf

English (PDF)
Published on: 6/04/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."